Genesis Biotechnology Group Announces Partnership with Yale University

HAMILTON, N.J., Oct. 30, 2018 /PRNewswire/ -- Genesis Biotechnology Group^® (GBG) and its CRO arm Genesis Drug Discovery & Development™ (GD³) announced today that it has entered into a partnership with Yale University to offer an integrated portfolio of drug discovery services from "target validation" to "lead optimization" to the awardees of the Blavatnik Fund for Innovation. The partnership is a part of GD³'s efforts to offer early drug discovery-based services to Yale's researchers, allowing their breakthrough research to get to the market as new drugs and treatments.

"We are delighted to partner with Yale University to accelerate the transition of fundamental biomedical discoveries into commercialization opportunities," said Olesia Buiakova, M.D., Ph.D., Chief Scientific Officer of GD³. "Our partnership with Yale is an important step forward for this program and we look forward to developing a strong and mutually beneficial relationship with the Blavatnik Fund and Office of Cooperative Research at Yale."

This partnership was made possible by a grant from the Blavatnik Family Foundation. This multi-year grant supports the Blavatnik Fund for Innovation at Yale, which was designed to bridge the gap between life science research and business and support faculty in the commercialization of applied research and technology. The fund's recent commitment of $25 million has created new opportunities for emerging ventures and biotech companies.

"Genesis Biotechnology Group has been a true collaborator for innovation. Since initiating this relationship, GBG has invested an unparalleled level of engagement with our investigators and we are excited to see this collaboration grow for years to come," said William Wiesler, Ph.D., M.B.A., Director of the Blavatnik Fund and Director of New Ventures at the Yale Office of Cooperative Research (OCR). "We're incredibly excited about the work ahead to advance drug discoveries and we're looking forward to the increase in opportunities for ventures in life sciences as afforded by the Blavatnik Fund."

 About GBG
GBG is a consortium of vertically integrated corporate research entities, which facilitates the overall market implementation and delivery of biomedical science products and services related to diagnostics and drug discovery. Through the consolidation of research activities, and the collaboration of diverse groups of scientists with expertise in molecular biology, genetics, high throughput screening (HTS), pharmacology, molecular modeling, and medicinal chemistry, GBG is well-positioned to create and sustain complex research platforms in drug discovery and the design of surrogate biomarkers for chronic diseases.

About Genesis Drug Discovery & Development
Genesis Drug Discovery & Development offers a comprehensive portfolio of drug discovery services in multiple therapeutic areas. From point solutions to program management, our experts in preclinical drug discovery ensure the efficient development and coordination unique preclinical programs from discovery through candidate selection. By providing a single point-of-contact throughout the project lifetime, GD³ streamlines transitions between all phases of the discovery cycle to shorten timelines for faster project completion and potential market advantage. Our mission is to leverage decades of Pharma and CRO experience and expertise to advance our client's mission of advancing therapies to patients and their physicians.

About The Blavatnik Fund for Innovation at Yale
The Blavatnik Fund for Innovation at Yale supports Yale faculty in the commercialization of applied research and technology in the life sciences. A significant obstacle to the development of early-stage university discoveries is the lack of funding for the proof-of-concept and validation studies needed to demonstrate commercial potential. To overcome this barrier, the Fund provides funding and business development support to help validate nascent technologies and identify potential industry partners to advance these technologies to the marketplace.

To find out more, please visit www.genesisbiotechgroup.com.

Contact: Prabal Banerjee, Ph.D., Business Development Executive
[email protected]

Contact: Mercy A. Quaye, Marketing and Communications Manager, OCR, Yale
203.432.1998
[email protected]

SOURCE Genesis Biotechnology Group

Related Links

http://www.genesisbiotechgroup.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED